Bortenat 3.5 mg injection is used for the treatment of multiple myeloma and mantle-cell lymphoma. It helps to prevent or slow down the growth of cancer cell by interfering with the protein mechanism of the cancerous cell. Bortenat 3.5 mg injection targets several factors essential for the survival of cancer cells, such as protein metabolism, bone marrow microenvironment, and cell signalling pathways. It acts on the protein metabolism to prevent cell survival and proliferation of cancer cells. It works to block the protein recycling system of cancer cell
Bortenat 3.5 mg injection is an anticancer medicine contains bortezomib, a proteasome inhibitor used to treat specific blood cancers, including multiple myeloma and mantle cell lymphoma (MCL). Bortezomib is an active FDA approved ingredient in Bortenat 3.5 mg injection can be prescribed alone or in combination with other anticancer medicines as per the treatment plan.
FDA Approval Timeline:
| 2003 | Approved for relapsed multiple myeloma |
| 2005 | Approved for mantle cell lymphoma |
| 2008 | Expanded approval for previously untreated multiple myeloma |
Bortenat 3.5 mg injection treats multiple myeloma (a cancer of the bone marrow) and mantle cell lymphoma (a type of cancer affecting the lymph nodes).
Multiple myeloma is a type of cancer that originates in the bone marrow, caused by the uncontrolled proliferation of white blood cells. This abnormality disrupts the routine function of normal plasma cells. Bortenat 3.5 mg injection works by disrupting the protein metabolism in malignant cells, causing excess toxicity in these cells. As a result, any further growth and proliferation of the cancer cells in the bone marrow.
Mantle cell lymphoma is a rare and aggressive form of Non-Hodgkin Lymphoma. In this indication, there is uncontrolled cell division of B-lymphocytes in the lymph nodes, leading to tumor formation. Bortenat 3.5 mg injection targets these malignant B-lymphocytes and disrupts their protein regulation. This process prevents any further growth of the tumor and supports other anticancer treatments.
The dosage for Bortenat 3.5 mg injection is based on the body surface area (BSA), which is measured in square meters (m²). This measure is used to support chemotherapy agents that act by spreading through the tissues, which makes BSA a better basal measurement than body weight.
1.3 mg/m² injections to be given twice a week for 2 weeks.
This regimen must be followed by a 10-day rest period (21-day cycle).
The injections must be given on Day 1, Day 4, Day 8, and Day 11.
For this indication, generally, any more dosing than the recommended dose is not ideal. Hence, the dose should not exceed 1.3 mg/m² per injection.
Generally, missed dose incidents are rare as Bortenat 3,5 mg is administered in healthcare institutions by professionals. Nevertheless, in case of a missed dose, patients must take the missed dose soon after remembering, provided that there is at least 72 hours left before the next scheduled dose.
Overdose of Bortenat 3.5 mg can lead to severe hypotension, thrombocytopenia, and serious toxicity. If patients observe any such symptoms, they must immediately seek medical attention.
1.3 mg/m² injections to be given twice a week in a 21-day cycle regimen.
The injections must be given on Day 1, Day 4, Day 8, and Day 11 along with other chemotherapy drugs.
For this indication, generally, any more dosing than the recommended dose is not ideal. Hence, the dose should not exceed 1.3 mg/m² per injection.
Generally, missed dose incidents are rare as Bortenat 3,5 mg is administered in healthcare institutions by professionals. Nevertheless, in case of a missed dose, patients must take the missed dose soon after remembering, provided that there is at least 72 hours left before the next scheduled dose
Overdose of Bortenat 3.5 mg can lead to blood pressure, platelet reduction, and organ toxicity. If patients observe any such symptoms, they must immediately seek medical attention.
You can buy Bortenat 3.5 mg injection from Lifesaving-meds.com at low price online with free shipping & free sample medicines. Lifesaving-meds.com provide Bortenat 3.5 mg injection at very less wholesale price for sale from India with low price guarantee, big discounts, free delivery, credit card / debit card, Zellepay, paypal, crypto / Bitcoin payment option & more in the United states of America (USA) – New York, California, Texas, Florida, Ohio, Oregon, Georgia, Denver, Illinois, Oregon, Pennsylvania, Washington, Wyoming & more; United Kingdom (UK) – London, Birmingham, Wales, Manchester & more; Europe (EU) – Moscow (Russia), Paris (France), Spain & more; and Australia (AU) – Sydney, Melbourne, Brisbane & more. So, buy Bortenat 3.5 mg injection near you when you are prescribed with this medication or search as Bortenat 3.5 mg injection for sale near me on google, bing, yahoo, duckducko, AOL & anywhere.
Bortenat 3.5mg Injection contains Bortezomib 3.5 mg, an anti-cancer medicine used for Multiple myeloma (blood/bone marrow cancer) & Mantle cell lymphoma (a type of cancer affecting the lymph nodes). Bortenat 3.5 mg injection works by blocking protein breakdown inside cancer cells, which helps stop their growth and causes cancer cell death.
Normally, in the human body, misfolded or unnecessary proteins are digested by a structure called the “proteosome,” which is located inside the cell. The proteosome is considered the recycling center of the cell as it contains enzymes that digest the unnecessary protein molecules, and the individual protein molecules, which can be used to form new protein molecules. This process is necessary to avoid the accumulation of unnecessary protein waste in the cell, which can cause harmful effects in the cell.
In cancer cells, the production of protein molecules is abnormally increased. In these cells, especially in myeloma cells, a large number of protein molecules are produced in the form of antibodies and other molecules. Hence, the proteosome functioning is essential in cancer cells. Bortenat 3.5 mg injection works by inhibiting this proteosome, especially the 26S proteosome, which is responsible for the degradation of protein molecules tagged by ubiquitin. As a result, there is a buildup of unneeded waste protein in the cells. In malignant cells, the buildup of misfolded and regulatory proteins leads to cellular stress. Excess buildup of toxic proteins generally leads to cell death by apoptosis (programmed cell death).
Another way by which Bortenat 3.5 mg destroys tumor cells is by targeting one of the major survival signalling pathways, the NF-κB (nuclear factor-kappa B). This signalling mechanism is essential to promote survival, inflammation, cell proliferation, and resistance to apoptosis. By interfering with the proteosome function, Bortenat 3.5 mg injection indirectly interrupts this signalling pathway in cancer cells. As a result, the cell survival signal in these cells is consistently “switched off.”
Additionally, Bortenat 3.5 mg injection also interferes with the cell cycle, preventing the cancer cells from proliferating any further. Bortenat 3,5 mg also affects the microenvironment around the tumor, which prevents the interaction between cancer cells and the surrounding bone marrow. This interaction is essential to provide proliferation signals to the cancer cells. By interfering with this interaction, Bortenat 3.5 mg injection prevents the multiplication of cancer cells.
Thus, by targeting multiple points in the metabolic and regulatory processes in the malignant cells, Bortenat 3.5 mg injection damages the cancer cells while slowly controlling the spread and effects of the tumor further.
Possible Side effects of Bortenat 3.5 mg injection
– > Blood and bone-marrow related
– > Nervous system
– > Gastrointestinal
– > General/systemic
– > Respiratory
– > Kidney and urinary
– > Liver related
– > Metabolic/serious complications
– > Most commonly reported effects of Bortenat 3.5 mg injection
The main indications treated using Bortenat 3.5 mg include Multiple Myeloma and Mantle Cell Lymphoma, which are certain types of cancers affecting white blood cells.
Bortenat 3.5 mg injection is administered by a medical professional in the form of intravenous (IV) or intramuscular (IM) injections.
The most common side effect caused by Bortenat 3.5 mg is peripheral neuropathy, which can result in numbness, tingling, or a burning sensation in the hands and feet.
Yes. Bortenat 3.5 mg injection can be used standalone or in combination with other anticancer drugs. However, this decision must be made by the medical care provider.
Bortenat 3.5 mg injection must not be consumed by pregnant women, as it can affect the growing fetus.
